RankAlpha logo
Back to Rankings

MTVA

MetaViaD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
View Chart
Current thesis
The post-earnings company materials kept the constructive operating story intact: DA-1726 Part 3 is underway, management is leaning into higher-dose titration to improve tolerability, and prior 48 mg data are being used to argue best-in-class potential in obesity and cardiometabolic disease [#8-K-2026-05-14] [#10-Q-2026-05-14].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Cash runway is guided only into Q4 2026, keeping dilution or other financing highly likely if development timelines slip [#10-Q-2026-05-14] [#10-K-2026-03-26].
Momentum
69
Value
59
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.00 · Bull $2.50 · Bear $0.40
Data freshness
Prices
As of 2026-06-03
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-03 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-03
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $61.67
Why
Momentum69 · Δ7d -
Value59 · Δ7d +17.7
Sentiment0 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
69
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
59
32% active weight
Current posture
7d trendImproving
Δ7d
+17.7
Δ21d
+1.1
Sentiment
0
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade D. Momentum 69.4 / Value 58.9 / Sentiment 0.0

Fundamentals (TTM)
As of 2026-06-02
Market Cap
$14M
Beta
0.28
Shares Out
2.2M
P/E (TTM) · Derived
-0.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.53
Rev YoY
-
EPS YoY
+75.0%
Gross Margin
-
Op Margin
-
Net Debt
-$16.02M
Current Ratio
1.74
As of 2026-06-03 • Updated nightlySource: Internal modelMethodology